Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

End-of-day quote. End-of-day quote  - 08/13
5.99 USD   +3.63%
01:55a TELIGENT : reports 2Q loss
07/28 TELIGENT, INC. : Announces Second Quarter 2016 Results
07/19 TELIGENT : Advances $50 Million Facility Expansion
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 65,7 M
EBIT 2016 1,16 M
Net income 2016 -10,3 M
Debt 2016 54,5 M
Yield 2016 -
Sales 2017 95,4 M
EBIT 2017 14,2 M
Net income 2017 -1,04 M
Debt 2017 62,8 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 7,22x
EV / Sales2017 5,07x
Capitalization 420 M
More Financials
Company
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
01:55a TELIGENT : reports 2Q loss
07/28 TELIGENT, INC. : Announces Second Quarter 2016 Results
07/28 TELIGENT, INC. : Results of Operations and Financial Condition, Financial Statem..
07/19 TELIGENT : Advances $50 Million Facility Expansion
07/13 TELIGENT, INC. : To Hold Conference Call For 2nd Quarter 2016 Results
07/12 TELIGENT : holds groundbreaking for major expansion project
07/11 TELIGENT INC. : breaks ground on expansion
07/08 TELIGENT, INC. : Receives Two FDA Approvals For Topical Prescription Portfolio
07/06 TELIGENT, INC. : Advances $50 Million Facility Expansion
07/06 TELIGENT : Advances $50 Million Facility Expansion
More news
Sector news : Pharmaceuticals - NEC
07:33pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
04:26pDJABBVIE : Results Boosted by Humira, Pipeline Growth
04:17pDJABBVIE : Results Boosted by Humira, Pipeline Growth
02:26pDJMerck Revenue Rises on Cancer, Hepatitis Treatments
02:10pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
More sector news : Pharmaceuticals - NEC
Advertisement
Chart IGI LABORIGI
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 9,50 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Sanjay Samudre Operations Director
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI89.51%420
JOHNSON & JOHNSON21.16%342 345
PFIZER INC.13.60%222 398
ROCHE HOLDING LTD.-9.99%215 597
NOVARTIS AG-5.30%214 061
MERCK & CO., INC.10.62%161 736
More Results